<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897582</url>
  </required_header>
  <id_info>
    <org_study_id>2018-05</org_study_id>
    <nct_id>NCT03897582</nct_id>
  </id_info>
  <brief_title>Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study</brief_title>
  <acronym>BLIPIC</acronym>
  <official_title>Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de Valenciennes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Bethune</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Douai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de Boulogne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier de Valenciennes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses
      necessary for this infection for patients treated with continuous veino-veinous hemodialysis.
      The pharmacokinetic variability expose to over and underdosage leading to toxicity or
      therapeutic failure. The aim of this study is to define if beta-lactams doses used in
      pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead
      to beta-lactam therapeutic plasma levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses
      necessary for this infection for patients treated with continuous veino-veinous hemodialysis.
      The pharmacokinetic variability expose to over and underdosage leading to toxicity or
      therapeutic failure. The aim of this study is to define if beta-lactams doses used in
      pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead
      to beta-lactam therapeutic plasma levels.

      This prospective observational multicenter study will include all patients with pneumonia
      treated by beta-lactam and continuous veino-veinous hemodialysis in 5 ICU. Blood sampling
      will be done at assumed pharmacokinetic steady state. Protocol sample concentrations of
      beta-lactams immediately prior to re-dosing, after 24 hours of association of intraveinous
      beta-lactam and continuous veino-veinous hemodialysis. Another sample will be done after 48
      hours. The ICU measured bacterial MICs routinely when the pathogen will be determined.
      Surveyed ICUs will adopt SFM-EUCAST breakpoints for the targeted (or suspected) bacteria to
      determine pharmacokinetic/pharmacodynamic targets when a mesured MIC (Minimum inhibitory
      concentration) is not available. Local hospital antibiogram data can also be used to describe
      likely pathogen susceptibility. Target attainment is defined as 100% fT&gt; 5 MIC. Due to the
      long delay to receive therapeutic drug monitoring results, doses could not be ajusted.
      Factors which could cause concentrations variations will be registered. When neurotoxicity is
      suspected, a sample will be realized to know beta-lactam concentration and the adverse event
      will be notified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of beta-lactams concentrations above plasma therapeutic levels</measure>
    <time_frame>Day 3 after start of antibiotic and continuous veino-veinous hemodialysis</time_frame>
    <description>We aimed to obtain concentrations over 5 MIC (Minimum inhibitory concentration) for at least 80% of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of steady state beta-lactam concentrations and their variability</measure>
    <time_frame>Day 3 after start of antibiotic and continuous veino-veinous hemodialysis</time_frame>
    <description>Description of beta-lactam concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neurotoxicity</measure>
    <time_frame>Day 7 after start of antibiotic and continuous veino-veinous hemodialysis</time_frame>
    <description>Percentage of neurotoxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends in beta-lactam concentrations between 2 days</measure>
    <time_frame>At Day 1 and Day 2</time_frame>
    <description>Comparaison between 24 hours and 48 hours samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response observed when beta-lactam concentrations achieved 5 MIC</measure>
    <time_frame>At Day 28 and day 90</time_frame>
    <description>Survival at Day 28 and Day 90</description>
  </secondary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Beta-lactam</condition>
  <condition>Continuous Renal Replacement Therapy</condition>
  <condition>Pneumonia</condition>
  <condition>Antibiotic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with pneumonia in ICU treated with intraveinous beta-lactams and CVVHD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years

          -  Receiving intraveinous beta-lactam : amoxicillin, amoxicillin-clavulanic acid,
             piperacillin-tazobactam, cefotaxime, ceftazidime, cefepime, meropenem, imipenem

          -  With AKI defined as any of the following, and treated with Multifiltrate Ci-Ca CVVHD
             1000® kit with a dialysis dose of 25 ml/kg/h :

               -  Increase in creatininemia ≥ 0.3 mg/dl (≥ 26.5 µmol/l) within 48 hours

               -  Increase in creatininemia ≥ 1.5 times baseline, which is known or presumed to
                  have occurred within the prior 7 days

               -  Urine volume &lt; 0.5 ml/kg/h for 6 hours

          -  Hospitalized in ICU

          -  Presence of a catheter to facilitate sample collection

          -  With pneumonia defined as any of the following :

               -  Chest X-ray pneumonia : opacities, new or progressive infiltrates

               -  AND at least one of the following : hyperthermia &gt; 38°C or hypothermia &lt; 36°C
                  with no other explanation ; leukopenia &lt; 4 G/L ou leukocytosis &gt; 12G/L

               -  AND at least one of the following : new onset purulent sputum or change in sputum
                  character, new onset or worsening cough or dyspnea or tachypnea, rales or
                  bronchial breathing, lower oxygen saturation/hypoxemia or increase of oxygen
                  needs or respiratory assistance

          -  Treated within 24 hours by citrate hemodialysis AND beta-lactam respecting dose and
             administration conditions of the study :

               -  Amoxicillin : loading dose followed immediately by 2g by extended infusion for 4
                  hours every 8 hours

               -  Amoxicillin-clavulanic acid : 2g every 8 hours by intermittent bolus

               -  Piperacillin-tazobactam: loading dose followed immediately by 4g/0.5g by
                  continuous infusion every 8 hours (&lt; 80 kg) ou 6 hours (&gt; 80 kg)

               -  Cefotaxime: loading dose followed immediately by 2g by continuous infusion every
                  8 hours Ceftazidime : loading dose followed immediately by 2g by continuous
                  infusion every 8 hours

               -  Cefepime: loading dose followed immediately by 2g by continuous infusion every 8
                  hours

               -  Meropenem : loading dose followed immediately by 2g (&gt; 60 kg) ou 1,33g (&lt; 60 kg)
                  by extended infusion for 4 hours every 8 hours

               -  Imipenem : loading dose followed immediately by 750 mg (&lt; 80 kg) ou 1g (&gt; 80 kg)
                  by extended infusion for 4 hours every 6 hours In case of extrem weight, dose
                  will be on investigator's discretion but administration conditions have be to
                  respected.

          -  No objection has been obtained from the patient or their legally authorised
             representative

        Exclusion Criteria:

          -  Aged &lt; 18 years

          -  ECMO

          -  Cystic fibrosis

          -  Burn victim

          -  Pregnant woman

          -  Any rapidly-progressing disease or immediately life-threatening illness

          -  Objection from the patients or their legally authorised representative

          -  No social security scheme

          -  Interruption of antibiotic before samples

          -  Patient in prison
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Lambiotte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier de Valenciennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabien Lambiotte, MD</last_name>
    <phone>+ 33 3 27 14 33 33</phone>
    <phone_ext>40258</phone_ext>
    <email>lambiotte-f@ch-valenciennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justine Lemtiri, Pharm D</last_name>
    <phone>+ 33 3 27 14 33 33</phone>
    <phone_ext>49732</phone_ext>
    <email>lemtiri-j@ch-valenciennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <state>Nord</state>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Matusik</last_name>
      <phone>+ 33 6 37 94 22 60</phone>
      <email>elodie.matusik@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hanane Fodil</last_name>
      <phone>+ 33 3 27 14 06 65</phone>
      <email>fodil-h@ch-valenciennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Guillaume Brunin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Van Grunderbeeck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Vinsonneau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chloé Rousselin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://sfar.org/optimisation-du-traitement-par-beta-lactamines-chez-le-patient-de-soins-critiques/</url>
    <description>SFAR, SFPT, Recommandations de Pratiques Professionnelles, Optimisation du traitement par bêta-lactamines chez le patient de soins critiques 2018.</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amoxicillin</keyword>
  <keyword>amoxicillin-clavulanic acid</keyword>
  <keyword>piperacillin-tazobactam</keyword>
  <keyword>cefotaxime</keyword>
  <keyword>ceftazidime</keyword>
  <keyword>cefepime</keyword>
  <keyword>meropenem</keyword>
  <keyword>imipenem</keyword>
  <keyword>multifiltrate</keyword>
  <keyword>citrate</keyword>
  <keyword>CVVHD</keyword>
  <keyword>extended and continuous infusion</keyword>
  <keyword>TDM</keyword>
  <keyword>Therapeutic Drug Monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

